Fig. 6.

Effect of dioscin in tumour-bearing mice of hypertrophy. (A) The schematic outline of dioscin treatment for tumour-bearing mice of hypertrophy. Nude mice were implanted with MDAMB- 231 cells. One week later, these mice were randomly subgrouped and subjected with transverse aorta constriction. Then these tumour-bearing mice were administrated with dioscin for 3 weeks (n = 8 per group). (B) The volume for tumor were measured each week (*P < 0.05 vs. Sham). (C) DNMT activities were determined in tumor tissues. (D) The methylation levels of Irf4 and Brac4 promoters were detected in tumor tissues. (E) The representative images for CD31 staining were presented in tumor tissues. (F) Representative M-mode echocardiography, the values for LVEF and LVFS and the ratios for HW/BW and HW/TL were showed in hypertrophic tumour-bearing mice with/without dioscin administration. (G) The mRNA levels of heart failure markers Anp, Bnp and β-Mhc in hearts were determined by qPCR assay. (H) Hematoxylin and eosin (HE) staining is shown (scale bar = 1 mm). (I) Representative images of WGA staining were presented (scale bar = 100 μm). (J) DNMT activities were measured in heart tissues from tumour-bearing mic. (K) ChIP-qPCR assay was performed to detect the methylation and NRF2 binding abilities at the promoters of Gpx3 (n = 6 per group). (L) The mRNA levels of Gpx3 were up-regulated in heart tissues from tumour-bearing hypertrophy after dioscin administration. (M) Correlation between mC level and NRF2 binding ability at the promoter of Gpx3 in heart tissues. N = 6 per group; *P < 0.05 vs. Sham, #P < 0.05 vs. TAC.